MPM BIOIMPACT
MPM BIOIMPACT is a Pre-seed, Seed, Series A, Series B and Series C+ fund in the US and Canada investing in Healthcare and healthcare-tech.
- Stages
- Pre-seed, Seed, Series A, Series B, Series C+
- Sectors
- Healthcare, healthcare-tech
- Invests in
- US-wide, Canada
- Actively investing
- Yes
- Founded
- 1996
- Assets under management
- $3.39B
- Website
- mpmcapital.com
Check size not disclosed
Thesis
MPM BioImpact is a venture capital firm founded in 1996 or 1997, headquartered in Boston, Massachusetts. The firm focuses on biotechnology investments, combining venture capital experience with impact investing. Since 2010, MPM has founded over 40 companies through its BioImpact strategy, emphasizing company creation and innovations in medicine. The firm invests in private and public companies involved in drug development, targeting transformative therapies for serious diseases. MPM BioImpact's investment strategy spans from pre-seed to Series C stages, focusing on the biotech and healthcare sectors. MPM manages over $3 billion in AUM across venture, hybrid, and hedge funds, primarily investing in the United States and Canada.
Common questions
Does MPM BIOIMPACT invest at the Pre-seed stage?
Yes. MPM BIOIMPACT lists Pre-seed, Seed, Series A, Series B and Series C+ among the stages it invests in.
Where does MPM BIOIMPACT invest?
MPM BIOIMPACT invests in the US and Canada.